Basic Medical Theory Research

[1] Kumar S K, Callander N S, Adekola K, et al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.[J]. Journal of the National Comprehensive Cancer Network :JNCCN.,2020,18(12):1685-1717.
[2] Rajkumar S V P, Dimopoulos M A P, Palumbo A P, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. The lancet oncology, 2014, 15(12): e538-e548.
[3] Siegel R L, Miller K D, Fuchs H E, et al. Cancer Stati stics, 2021[J]. CA: a cancer journal for clinicians, 2021, 71(1):7-33.
[4] Brigle K, Rogers B. Pathobiology and Diagnosis of Multiple Myeloma[J]. Seminars in Oncology Nursing, 2017,33(3): 225-236.
[5] Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis[J]. Frontiers in Oncology, 2020, 9.
[6] Storb R. Edward Donnall Thomas (1920-2012)[J]. Nature,2012, 491(7424): 334.
[7] 邓书会,安刚,邱录贵.多发性骨髓瘤的新药研发与治疗现状[J].中国肿瘤临床,2020,47(22):1135-1139.
[8] McElwain T J, Powles R L. High-dose intravenous melpha lan for plasma-cell leukaemia and myeloma.[J]. Lancet., 1983, 2(8354):822-824.
[9] Barlogie B, Alexanian R, Dicke K, et al. High-dose chemoradiotherapy and autologous bone marrow transplantati on for resistant multiple myeloma.[J]. Blood, 1987, 70(3): 869-872.
[10] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalido mide, Bortezomib, and Dexamethasone with Transplantation for Myeloma[J]. New England Journal of Medicine, 2017, 376(14): 1311-1320.
[11] Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan -prednisone,with or without bortezomib-lenalidomide-dexa methasone consolidation therapy, and lenalidomide maintena nce for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study[J]. The Lancet Haematology,2020,7(6):e456-e468.
[12] 中华医学会血液学分会浆细胞疾病学组,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤自体造血干细胞移植指南(2021年版)[J].中华血液学杂志,2021,42(05):353-357.
[13] DimopoulosMA,MoreauP,TerposE,etal.Multiplemyeloma:EHA-ESMOClinicalPracticeGuidelinesfordiagnosis,treatmentandfollowup†[J].AnnalsofOncology,2021, 32(3): 309-322.
[14] Lemieux C, Muffly L S, Rezvani A, et al. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma[J]. Bone Marrow Transplantation, 2021, 56(2): 368-375.
[15] Pawlyn C, Cairns D, Menzies T, et al. Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial[J]. Haematologica, 2020, Online ahead of print.
[16] Antonioli E, Nozzoli C, Buda G, et al. Autologous stem cell transplantation is safe in selected elderly multiplemyeloma patients[J]. European Journal of Haematology, 2020, 104(2):138-144.
[17] Remenyi P, Varga G, Mikala G, et al. Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years[J].Transplantation Proceedings,2016,48(1):177-184.
[18] Jain T,Sonbol M B,Firwana B,et al.High Dose Chemothe rapy with Early Autologous Stem CellTransplantation Compa red to Standard Dose Chemotherapy orDelayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis[J]. 2019, 25(2): 239-247.
[19] Lehners N, Becker N, Benner A, et al. Analysis of longterm survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response[J]. Cancer medicine (Malden,MA), 2018,7(2):307-316.
[20] 曾添美,何海燕,石昊天,等.PAD与TAD方案治疗新诊断多发性骨髓瘤患者的疗效比较及预后分析 [J].中华医学杂志,2015,95(10):731-735.
[21] 王慧娟,杨光忠,周慧星,等.VRD与VCD方案诱导治疗后序贯自体造血干细胞移植对新诊断的多发性骨髓瘤患者的疗效分析[J].首都医科大学学报,2021,42(4):615-622.
[22] UttervallK,Borg Bruchfeld J, Gran C, et al. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma[J]. European journal of haematology, 2019, 103(3): 247-254.
[23] Paul B, Lipe B, Ocio E M, et al. Induction Therapy for Newly Diagnosed Multiple Myeloma[J]. American Society of Clinical Oncology educational book, 2019,39:e176-e186.
[24] Wester R, van der Holt B, Asselbergs E, et al. Phase II study of carfilzomib, thalidomide, and low-dose dexamethas one as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial[J]. Haematologica, 2019, 104(11): 2265-2273.
[25] Mateos M, Dimopoulos M A, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma[J]. The New England journal of medicine, 2018,378 (6):518-528.
[26] Moreau P,Attal M, Hulin C, et al. Bortezomib, thalido mide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, openlabel, phase 3 study[J].The Lancet (British edition),2019,394 (10192):29-38.
[27] Cao Y, Zhao L, Zhang T, et al. Cost-Effectiveness Analy sis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma[J]. Frontiers in Pharmacology,2021,12.
[28] Mahajan S, Tandon N, Kumar S. The evolution of stem -cell transplantation in multiple myeloma[J]. Therapeutic Advances in Hematology,2018,9(5):123-133.
[29] Mohty M, Huebel K, Kroeger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the Europ ean Group for Blood and Marrow Transplantation[J]. Bone marrow transplantation (Basingstoke), 2014, 49(7): 865-872.
[30] Anu P, Antti T, Raija S, et al. Comparison of CD34+ cell mobilization, blood graft cellular composition, and post-transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low-dose cyclophospha mide: A prospective multicenter study[J]. Transfusion, 2021.
[31] Danylesko I, Sareli R, Varda-Bloom N, et al. Longacting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant ation[J]. International Journal of Hematology, 2021, 114(3):363-372.
[32] Duong H K, Savani B N, Copelan E, et al. PeripheralBlood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantat ion[J]. Biology of Blood and Marrow Transplantation, 2014,20(9):1262-1273.
[33] Gonsalves W I, Buadi F K, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement[J]. Bone Marrow Transplant, 2019, 54(3): 353-367.
[34] Mikhael J, Ismaila N, Cheung M C, et al. ASCO Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline[J]. J Clin Oncol,2019,37(14): 1288-12163.
[35] Srour S A, Milton D R, Bashir Q, et al. Melphalan dose intensity for autologous stem cell transplantation in multi ple myeloma[J]. Haematologica, 2021.
[36] Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Mye´lome 9502 randomized trial[J]. Blood, 2002,99(3):731-735.
[37] Bashir Q, Thall P F, Milton D R, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial[J]. The Lancet Haematology,2019,6(5): e266-e275.
[38] Sengsayadeth S, Malard F, Savani B N, et al. Posttra nsplant maintenance therapy in multiple myeloma: the changing landscape[J]. Blood Cancer Journal, 2017, 7(3): e545.
[39] Luo J, Gagne J J, Landon J, et al. Comparative effe ctiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study[J]. European Journal of Cancer, 2017, 70: 22-33.
[40] Li A, Wu Q, Warnick G, et al. The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma[J]. Ann Hematol, 2020, 99(1): 121-126.
[41] Ludwig H, Durie B G, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma[J]. Blood, 2012,119(13): 3003-3015.
[42] Gay F, Jackson G, Rosiñol L, et al. Maintenance Treat ment and Survival in Patients With Myeloma[J]. JAMA Oncology, 2018, 4(10):1389.
[43] Cavo M, Goldschmidt H, Rosinol L, et al. Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies[J]. Blood, 2018,132(Supplement 1):124.
[44] Sonneveld P, van der Holt B, Segeren C M, et al.Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial[J]. Haematologica,2007, 92(7): 928-935.
[45] Blocka J, Hielscher T, Goldschmidt H, et al. Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Progno stic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients[J]. Biology of Blood and Marrow Transplantation, 2020, 26(7): 1280-1287.